100 related articles for article (PubMed ID: 15566301)
1. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
Laufer SA; Zimmermann W; Ruff KJ
J Med Chem; 2004 Dec; 47(25):6311-25. PubMed ID: 15566301
[TBL] [Abstract][Full Text] [Related]
2. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
3. Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
Laufer SA; Striegel HG; Wagner GK
J Med Chem; 2002 Oct; 45(21):4695-705. PubMed ID: 12361396
[TBL] [Abstract][Full Text] [Related]
4. From imidazoles to pyrimidines: new inhibitors of cytokine release.
Laufer SA; Wagner GK
J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
[TBL] [Abstract][Full Text] [Related]
7. Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors.
Romeiro NC; Albuquerque MG; de Alencastro RB; Ravi M; Hopfinger AJ
J Comput Aided Mol Des; 2005 Jun; 19(6):385-400. PubMed ID: 16231199
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of proinflammatory cytokine pathway inhibitors for p38 MAPK inhibitory potential.
Kadam RU; Garg D; Paul AT; Bhutani KK; Roy N
J Med Chem; 2007 Dec; 50(25):6337-42. PubMed ID: 17988083
[TBL] [Abstract][Full Text] [Related]
13. Small molecular anti-cytokine agents.
Wagner G; Laufer S
Med Res Rev; 2006 Jan; 26(1):1-62. PubMed ID: 16283677
[TBL] [Abstract][Full Text] [Related]
14. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Trifilieff A; Keller TH; Press NJ; Howe T; Gedeck P; Beer D; Walker C
Br J Pharmacol; 2005 Apr; 144(7):1002-10. PubMed ID: 15685201
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines.
Tariq S; Alam O; Amir M
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883
[TBL] [Abstract][Full Text] [Related]
16. P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model.
Dong X; Liu Y; Du M; Wang Q; Yu CT; Fan X
Eur J Cardiothorac Surg; 2006 Jul; 30(1):77-84. PubMed ID: 16723252
[TBL] [Abstract][Full Text] [Related]
17. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
[TBL] [Abstract][Full Text] [Related]
18. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
[TBL] [Abstract][Full Text] [Related]
19. The role of p38 mitogen-activated protein kinase in IL-1 beta transcription.
Baldassare JJ; Bi Y; Bellone CJ
J Immunol; 1999 May; 162(9):5367-73. PubMed ID: 10228013
[TBL] [Abstract][Full Text] [Related]
20. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.
Westra J; Doornbos-van der Meer B; de Boer P; van Leeuwen MA; van Rijswijk MH; Limburg PC
Arthritis Res Ther; 2004; 6(4):R384-92. PubMed ID: 15225374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
